Table 1.
Descriptive Sample Statistics
| Visit | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||||||
| Baseline | 1 | 3 | 6 | 9 | 12 | 15 | 18 | |||||||||
| n | % | Mean (SD) | n | Mean (SD) | n | Mean (SD) | n | Mean (SD) | n | Mean (SD) | n | Mean (SD) | n | Mean (SD) | n | |
| Age (Mean, SD) | 40.9 | 11.03 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Male | 559 | 73.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| European American (EA) | 437 | 57.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| African American (AA) | 222 | 29.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Race | 106 | 14.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Years in Treatment (Mean, SD) | 16.7 | 11.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Olanzapine | 173 | 24.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Perphenazine | 119 | 15.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Quetiapine | 160 | 20.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Risperidone | 159 | 20.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Ziprasidone | 90 | 11.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| PGI (Mean, SD) | 3.55 | 1.51 | 3.13 (1.51) | 668 | 3.16 (1.45) | 614 | 3.19 (1.42) | 608 | 3.02 (1.42) | 571 | 3.07 (1.41) | 558 | 3.09 (1.43) | 535 | 3.36 (1.31) | 90 |
| CGI-S (Mean, SD) | 3.92 | 0.95 | 3.63 (0.95) | 667 | 3.52 (0.91) | 613 | 3.51 (0.95) | 603 | 3.39 (0.98) | 572 | 3.35 (0.98) | 557 | 3.33 (0.97) | 534 | 3.45 (0.90) | 90 |